Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

May 5, 2015

Preclinical Data on EBI-031 Demonstrates Potent IL-6 Inhibition and Extended Vitreal Retention

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

May 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced six abstracts have been accepted for one oral and five poster presentations at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentations will detail data from research programs across a broad range of disease areas, including cancer, hematologic (blood) and ophthalmic (eye) diseases. The meeting will take place May 13-16 at the Hyatt Regency in New Orleans. Following is a schedule of Editas’ poster and oral presentations:

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

May 5, 2015

Scaling Entrepreneurial Innovations in Life Sciences

Syros Pharmaceuticals Augments Senior Leadership Team

Syros Pharmaceuticals Augments Senior Leadership Team

April 30, 2015

Adds significant depth to chemistry, corporate development and finance functions

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, today announced the addition of three senior members to the company. Jonathan Garen joins the Company as Chief Business Officer; Christopher Roberts, Ph.D., as Vice President of Chemistry and Early Development; and Colleen DeSimone as Vice President of Finance and Controller.

Eleven Biotherapeutics Reports First Quarter 2015 Financial Results

Eleven Biotherapeutics Reports First Quarter 2015 Financial Results

April 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2015, and recent business highlights.

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

April 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease.

Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis

Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis

April 29, 2015

Phase 2 Results Published in Eye and Contact Lens Demonstrate Statistically Significant and Clinically Meaningful

Improvements with EBI-005 and Support Planned Phase 3 Clinical Study Design

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

April 29, 2015

 Brain-penetrant, pan-IDH mutant inhibitor broadens pipeline for treatment of patients with IDH mutant positive cancers

Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer

Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer

April 27, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Vic Myer, Ph.D., as chief technology officer. Dr. Myer brings to Editas extensive experience in leading pharmaceutical and technology research and development, information technology and business development.

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

April 21, 2015

First Product from The Pentarin™ Platform, A Novel Class of Miniaturized Biologic Drug Conjugates (mBDCs) Incorporated in Nanoparticles

Data Presented at AACR Annual Meeting